Abstract
Temozolomide, an oral alkylating agent, is a commonly used medicine in the treatment of anaplastic astrocytoma and glioblastoma multiforme. This paper will present the mechanism of action as well as the clinical role for this chemotherapeutic drug.
Highlights
Temozolomide (Temodar) is an oral alkylating agent approved by the FDA for use in the first-line treatment of glioblastoma multiforme as well as for recurrent anaplastic astrocytoma.[1]
The proposed mechanism of action is based on the ability of its metabolites to deposit methyl groups on DNA guanine bases
MTIC methylates a number of nucleobases, most important, the guanine base
Summary
Temozolomide (Temodar) is an oral alkylating agent approved by the FDA for use in the first-line treatment of glioblastoma multiforme as well as for recurrent anaplastic astrocytoma.[1]. Proposed Mechanism of Action Temozolomide is an oral alkylating agent, first developed in the early 1980s at Aston University in Great Britain.[3] The proposed mechanism of action is based on the ability of its metabolites to deposit methyl groups on DNA guanine bases. The prodrug temozolomide is readily absorbed in the small intestine, with good penetration of the blood-brain barrier due to its small size (194 Da).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
